Subscribe To Our Free Newsletter |
Why brokerages are positive on Torrent
Even as the broader markets were under pressure, the stock of Torrent Pharmaceuticals was down 1.05 per cent on October 26. This was on expectation that steady sales growth momentum in core markets such as India and Brazil and recovery in the US market coupled with margin expansion will drive strong earnings growth over the next couple of years. Brokerages are working with the net profit growth of 28-34 per cent annually over the FY23-25 period.